ImmuPharma PLC banner

ImmuPharma PLC
LSE:IMM

Watchlist Manager
ImmuPharma PLC Logo
ImmuPharma PLC
LSE:IMM
Watchlist
Price: 6.64 GBX -1.48% Market Closed
Market Cap: £33.4m

Balance Sheet

Balance Sheet Decomposition
ImmuPharma PLC

Balance Sheet
ImmuPharma PLC

Rotate your device to view
Balance Sheet
Currency: GBP
Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
6
3
12
23
16
12
9
5
5
1
2
3
5
1
6
2
1
0
0
Cash
0
3
12
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash Equivalents
6
0
0
0
16
12
9
5
5
1
2
3
5
1
6
2
1
0
0
Total Receivables
0
0
0
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
0
Accounts Receivables
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Receivables
0
0
0
1
1
1
1
1
1
1
0
0
0
0
0
0
1
1
0
Other Current Assets
0
0
0
0
0
0
0
0
0
1
3
1
0
2
1
1
0
0
0
Total Current Assets
7
3
13
24
17
13
10
7
6
2
6
4
6
4
7
3
2
1
1
PP&E Net
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
PP&E Gross
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Accumulated Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
0
0
Intangible Assets
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
Goodwill
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
2
1
2
1
1
1
0
Other Long-Term Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
Other Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Assets
7
N/A
4
-44%
13
+227%
25
+84%
18
-29%
14
-19%
11
-26%
7
-31%
7
-2%
3
-55%
7
+109%
5
-25%
9
+73%
6
-33%
11
+88%
6
-45%
4
-34%
3
-32%
1
-64%
Liabilities
Accounts Payable
0
0
0
4
0
0
0
0
0
1
1
1
1
0
0
1
1
1
1
Accrued Liabilities
1
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Current Liabilities
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Current Liabilities
1
1
1
6
1
1
1
1
1
1
1
1
1
1
1
2
1
2
2
Long-Term Debt
0
0
1
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Liabilities
1
N/A
1
-27%
2
+106%
7
+204%
2
-76%
2
+12%
2
+18%
2
-14%
1
-24%
2
+11%
1
-24%
1
+24%
1
-28%
1
-49%
1
+137%
2
+26%
1
-8%
2
+15%
2
-9%
Equity
Common Stock
7
7
8
8
8
10
8
10
9
11
14
16
18
23
25
28
29
30
30
Retained Earnings
5
8
2
3
0
3
7
11
14
17
23
29
36
44
41
50
54
57
59
Additional Paid In Capital
4
4
5
7
7
7
7
8
10
10
16
19
27
27
27
27
29
29
29
Other Equity
0
0
0
0
0
1
0
2
0
2
2
2
2
1
1
1
1
1
1
Total Equity
6
N/A
3
-48%
11
+269%
18
+61%
16
-12%
13
-22%
8
-33%
5
-36%
6
+6%
2
-70%
6
+228%
4
-36%
8
+113%
5
-31%
10
+83%
4
-54%
3
-43%
1
-58%
1
N/A
Total Liabilities & Equity
7
N/A
4
-44%
13
+227%
25
+84%
18
-29%
14
-19%
11
-26%
7
-31%
7
-2%
3
-55%
7
+109%
5
-25%
9
+73%
6
-33%
11
+88%
6
-45%
4
-34%
3
-32%
1
-64%
Shares Outstanding
Common Shares Outstanding
73
73
77
81
82
82
82
82
89
89
125
133
139
167
250
285
333
416
416
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett